Table 2.
Surface under the cumulative ranking curve (SUCRA) by NMA $.
| Study rank | Lifestyle | Exercise | Diet | Orlistat | Acarbose/Voglibose | Metformin/Flumamine | Pioglitazone/Rosiglitazone | Pitavastatin | Glipizide | Herbal medicine | Placebo | Standard |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Worst | 0.0 | 0.0 | 0.1 | 0.4 | 0.0 | 0.0 | 4.1 | 8.0 | 6.7 | 1.3 | 77.0 | 2.5 |
| Mean | 4.4 | 3.1 | 5.4 | 3.6 | 5.4 | 6.0 | 9.6 | 8.2 | 3.0 | 7.7 | 11.7 | 9.5 |
| SUCRA | 0.7 | 0.8 | 0.6 | 0.8 | 0.6 | 0.5 | 0.2 | 0.3 | 0.8 | 0.4 | 0.0 | 0.2 |
$: By MVMETA assuming the minimum parameter is the best, using 5000 draws, allowing for parameter uncertainty. Worst (%) denotes the estimated probabilities (%) of each treatment being the worst rank (0%: best to 100%: worst). Mean rank denotes average rank in the 12 treatments for 5000 repeatments (1: best to 12: worst). SUCRA is the surface under cumulative ranking curve (1: best to 0: worst). Bold shows interventions with (Worst = 0%, Mean rank < 5, or SUCRA ≥ 0.7).